Randomized phase II study of capecitabine plus cisplatin with or without sorafenib in patients with metastatic gastric cancer (STARGATE)

BACKGROUND: In this randomized phase II study, we evaluated the efficacy and safety of sorafenib in combination with capecitabine and cisplatin (XP) as first‐line chemotherapy in advanced gastric cancer. PATIENTS AND METHODS: Patients with metastatic gastric or gastroesophageal junction adenocarcino...

Descripción completa

Detalles Bibliográficos
Autores principales: Ryu, Min‐Hee, Lee, Kyung Hee, Shen, Lin, Yeh, Kun‐Huei, Yoo, Changhoon, Hong, Young Seon, Park, Young Iee, Yang, Sung Hyun, Shin, Dong Bok, Zang, Dae Young, Kang, Won Ki, Chung, Ik‐Joo, Kim, Yeul Hong, Ryoo, Baek‐Yeol, Nam, Byung‐Ho, Park, Young Soo, Kang, Yoon‐Koo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134272/
https://www.ncbi.nlm.nih.gov/pubmed/36515003
http://dx.doi.org/10.1002/cam4.5536

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134272/
https://www.ncbi.nlm.nih.gov/pubmed/36515003
http://dx.doi.org/10.1002/cam4.5536

Ejemplares similares